UA87980C2 - Композиция для улучшения познания и памяти - Google Patents

Композиция для улучшения познания и памяти

Info

Publication number
UA87980C2
UA87980C2 UAA200511154A UAA200511154A UA87980C2 UA 87980 C2 UA87980 C2 UA 87980C2 UA A200511154 A UAA200511154 A UA A200511154A UA A200511154 A UAA200511154 A UA A200511154A UA 87980 C2 UA87980 C2 UA 87980C2
Authority
UA
Ukraine
Prior art keywords
impairment
melatonin
memory
nicotine
utility
Prior art date
Application number
UAA200511154A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нава Зисапель
Мойше Лаудон
Original Assignee
Неурим Фармасеутикалс (1991) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Неурим Фармасеутикалс (1991) Лтд. filed Critical Неурим Фармасеутикалс (1991) Лтд.
Publication of UA87980C2 publication Critical patent/UA87980C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается фармакологически активной композиции, полезной для лечения бессонницы, которая содержит: (а) по крайней мере, один первый действующий компонент, выбранный из мелатонина, других мелатонергических веществ, агонистов мелатонина и антагонистов мелатонина; и (б) по крайней мере, один второй действующий компонент, выбранный из никотина и агонистов рецепторов никотина; для использования лекарственного средства, которое содержит компонент (а) с компонентом (б) или без него, с целью облегчения, по крайней мере, одного из вредных явлений, которые имеют место у больного в ходе никотинзаменяемой терапии или иным образом выбранные среди ухудшения качества сна, ухудшения когнитивных функций и ухудшения памяти, а также комплект, полезный при лечении расстройств сна, который содержит компоненты (а) и (б) в виде лекарствен�
UAA200511154A 2003-04-29 2004-04-15 Композиция для улучшения познания и памяти UA87980C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL155666A IL155666A (en) 2003-04-29 2003-04-29 Insomnia treatment

Publications (1)

Publication Number Publication Date
UA87980C2 true UA87980C2 (ru) 2009-09-10

Family

ID=33397641

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200511154A UA87980C2 (ru) 2003-04-29 2004-04-15 Композиция для улучшения познания и памяти

Country Status (29)

Country Link
US (2) US8859593B2 (ru)
EP (1) EP1620058B1 (ru)
JP (2) JP4981440B2 (ru)
KR (1) KR101136885B1 (ru)
CN (1) CN1787820B (ru)
AR (1) AR048370A1 (ru)
AT (1) ATE539746T1 (ru)
BR (1) BRPI0409935A (ru)
CA (1) CA2521182C (ru)
CL (1) CL2004000877A1 (ru)
CY (1) CY1112689T1 (ru)
DK (1) DK1620058T3 (ru)
EA (1) EA008768B1 (ru)
ES (1) ES2380364T3 (ru)
HK (1) HK1087635A1 (ru)
IL (1) IL155666A (ru)
IS (1) IS8090A (ru)
MX (1) MXPA05011590A (ru)
NO (1) NO333015B1 (ru)
NZ (1) NZ542724A (ru)
PE (1) PE20050144A1 (ru)
PL (1) PL1620058T3 (ru)
PT (1) PT1620058E (ru)
SI (1) SI1620058T1 (ru)
TW (1) TWI340037B (ru)
UA (1) UA87980C2 (ru)
UY (1) UY28296A1 (ru)
WO (1) WO2004096118A2 (ru)
ZA (1) ZA200509508B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
US8372876B2 (en) * 2007-03-06 2013-02-12 The University Of Houston System Method for improving memory in mammals
AU2008228903B2 (en) 2007-03-19 2013-03-07 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin B12
MX2009011002A (es) 2007-04-12 2010-03-15 Univ Minnesota Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
CN105142630A (zh) * 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
ES2738633T3 (es) * 2015-02-04 2020-01-24 Soeur Josefa Menendez Sistema terapéutico transdérmico que contiene valentonina y su uso como medicamento
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
EP3777842A1 (en) 2016-10-31 2021-02-17 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
KR102499141B1 (ko) * 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468017A (en) * 1892-02-02 Lock-case
US4506080A (en) * 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
ATE71287T1 (de) * 1986-06-13 1992-01-15 Alza Corp Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit.
DE3639418A1 (de) 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
CA2116036A1 (en) * 1991-10-18 1993-04-29 F. Eugene Yates Device for the transdermal administration of melatonin
WO1993014200A1 (en) * 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
ATE141051T1 (de) * 1992-04-07 1996-08-15 Neurim Pharma 1991 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
AU7323794A (en) * 1993-07-09 1995-02-06 Cygnus Therapeutic Systems Method and device for providing nicotine replacement therapy transdermally/transbuccally
WO1995028144A1 (en) * 1994-04-13 1995-10-26 Ciba-Geigy Ag Temporally controlled drug delivery systems
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
WO1996023496A1 (en) 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
EP0906089B1 (en) 1996-05-13 2003-08-27 Novartis Consumer Health S.A. Buccal delivery system
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
JP2002500652A (ja) * 1997-05-30 2002-01-08 ニューロサーアチ・アクティーゼルスカブ スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
US6274615B1 (en) * 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
AU5787999A (en) 1998-08-26 2000-03-21 Andrei Zakharovich Afanasiev Method for treating neurodegenerative disorders
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
ATE252380T1 (de) * 1999-02-05 2003-11-15 Cipla Ltd Topische sprays enthaltend eine filmbildende zusammensetzung
US6353051B1 (en) * 1999-03-10 2002-03-05 E. I. Du Pont De Nemours And Company Top coating for synthetic leathers
EP1272177B1 (en) 2000-01-05 2007-04-11 Neurim Pharmaceuticals (1991) Limited Method and formulation for treating resistance to antihypertensives and related conditions
PT1311272E (pt) * 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
DE10013712A1 (de) 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
US6486172B2 (en) * 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
BR0208382A (pt) 2001-03-26 2004-06-15 Smithkline Beecham Corp Forma de dosagem oral contendo nicotina
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
EP1304048B1 (en) * 2001-10-22 2004-09-22 Ivo Pera Composition to reduce or quit smoking addiction
US7113651B2 (en) * 2002-11-20 2006-09-26 Dmetrix, Inc. Multi-spectral miniature microscope array
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment

Also Published As

Publication number Publication date
NO333015B1 (no) 2013-02-18
PE20050144A1 (es) 2005-05-12
KR101136885B1 (ko) 2012-04-20
SI1620058T1 (sl) 2012-05-31
TW200501948A (en) 2005-01-16
CN1787820A (zh) 2006-06-14
NZ542724A (en) 2007-05-31
EA200501666A1 (ru) 2006-06-30
AR048370A1 (es) 2006-04-26
EP1620058A2 (en) 2006-02-01
JP2006525317A (ja) 2006-11-09
IL155666A (en) 2013-12-31
IL155666A0 (en) 2004-09-27
CA2521182C (en) 2011-05-31
JP4981440B2 (ja) 2012-07-18
DK1620058T3 (da) 2012-05-07
EP1620058B1 (en) 2012-01-04
MXPA05011590A (es) 2006-03-08
ATE539746T1 (de) 2012-01-15
ES2380364T3 (es) 2012-05-11
CN1787820B (zh) 2010-05-05
NO20055531L (no) 2005-11-23
KR20060005402A (ko) 2006-01-17
HK1087635A1 (en) 2006-10-20
UY28296A1 (es) 2004-11-30
JP2012116859A (ja) 2012-06-21
EP1620058A4 (en) 2006-07-26
EA008768B1 (ru) 2007-08-31
CY1112689T1 (el) 2016-02-10
IS8090A (is) 2005-10-25
US20060229340A1 (en) 2006-10-12
WO2004096118B1 (en) 2005-12-01
TWI340037B (en) 2011-04-11
US8859593B2 (en) 2014-10-14
US20140378512A1 (en) 2014-12-25
CL2004000877A1 (es) 2005-01-07
CA2521182A1 (en) 2004-11-11
PT1620058E (pt) 2012-04-13
BRPI0409935A (pt) 2006-04-25
WO2004096118A3 (en) 2005-10-13
ZA200509508B (en) 2006-11-29
PL1620058T3 (pl) 2012-07-31
WO2004096118A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
ATE454140T1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
HK1095138A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
MXPA05011064A (es) Combinaciones de paroxetina y [1-(r)-(3, 5-bis-trifluorometi l-fenil)-etil] -metilamida del acido 4-(s)- (4-acetil-piperazin -1-il)-2- (r)-(4-fluoro -2-metil- fenil)-piperidin -1-carboxilico para tratamiento de depresion y/o ansiedad.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
MY136683A (en) Kappa opoid agonist for the treatment of irritable bladder
TH70531B (th) องค์ประกอบสำหรับปรับปรุงกระบวนการรับรู้และความจำให้ดีขึ้น
TH69871A (th) องค์ประกอบสำหรับปรับปรุงกระบวนการรับรู้และความจำให้ดีขึ้น